|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
4.575 -0.055 (-1.188%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Turnover | 7,100,797 | -6.331% | 7,580,699 | 6,542,690 | 6,739,100 | 5,712,259 |
| Cost of Sales | (4,597,895) | -7.629% | (4,977,637) | (4,278,866) | (4,466,133) | (3,331,598) |
| Gross Profit | 2,502,902 | -3.848% | 2,603,062 | 2,263,824 | 2,272,967 | 2,380,661 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (70,642) | 45.678% | (48,492) | (109,083) | (94,934) | (137,588) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | (613) | (93) | (17) | |
| Share of Results of Asso. & JCEs | (1,732) | 91.593% | (904) | 13,636 | 5,214 | 5,840 | |
| Profit / (Loss) before Taxation | 1,745,906 | 0.264% | 1,741,315 | 1,618,674 | 1,564,475 | 1,504,802 | |
| Taxation | (400,483) | -1.380% | (406,088) | (366,501) | (369,721) | (328,442) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (61,861) | -19.052% | (76,421) | (79,209) | (54,901) | (51,167) | |
| Others | (21,033) | -31.428% | (30,673) | (35,729) | (42,793) | (35,828) | |
| Profit / (Loss) Attributable to Shareholders | 1,262,529 | 2.801% | 1,228,133 | 1,137,235 | 1,097,060 | 1,089,365 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 13,122 | -24.268% | 17,327 | (6,014) | (34,288) | (23,108) |
| Depreciation & Amortisation | 407,755 | 19.001% | 342,648 | 262,063 | 244,826 | 196,609 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 63.000 | -3.077% | 65.000 | 60.000 | 58.000 | 58.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 9.911 | -- | 9.337 | 8.940 | 7.738 | 6.987 |
| Remarks: | Real time quote last updated: 11/09/2026 09:49 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,262,529 |
| %Change | 2.801% |
| EPS / (LPS) | RMB 0.630 |
| NBV Per Share (¥) | RMB 9.911 |